Related Experiment Video
Updated: Feb 23, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
Maeva Dufies1,2, Sandy Giuliano1,2, Julien Viotti3
1University of Nice Sophia Antipolis, Institute for Research on Cancer and Aging of Nice, CNRS UMR 7284, INSERM U1081, 33 av. Valombrose, Centre Antoine Lacassagne, France.
Background:
Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis.
Methods:
Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). The plasmatic level of CXCL7 at baseline was correlated with progression-free survival (PFS).
Results:
The cut-off value of CXCL7 for PFS was 250 ng ml-1. Patients with CXCL7 plasmatic levels above the cut-off at baseline (250 ng ml-1) had a significantly longer PFS (hazard ratio 0.323 (95% confidence interval 0.147-0.707), P=0.001). These results were confirmed in a retrospective validation cohort. The levels of CXCL7 did not influence PFS of the bevacizumab-treated patients.
Conclusions:
CXCL7 may be considered as a predictive marker of sunitinib efficacy for ccRCC patients.
Insights
High baseline CXCL7 levels predict longer progression-free survival in metastatic clear cell renal cell carcinoma (ccRCC) patients treated with sunitinib. This finding may help personalize ccRCC treatment strategies.
Area of Science:
- Oncology
- Biomarker Discovery
- Renal Cell Carcinoma Research
Background:
- Metastatic clear cell renal cell carcinoma (ccRCC) treatment relies on sunitinib, a first-line therapy with limited efficacy (median progression <1 year).
- There is a critical need for predictive markers to personalize ccRCC treatment at diagnosis and improve patient outcomes.
Purpose of the Study:
- To identify predictive biomarkers for sunitinib response in first-line metastatic ccRCC patients.
- To evaluate the association between baseline plasmatic CXCL7 levels and progression-free survival (PFS).
Main Methods:
- Prospective phase 2 multi-center trials (SUVEGIL and TORAVA) involving 54 patients on sunitinib and 45 on bevacizumab.
- Correlation analysis of baseline plasmatic CXCL7 levels with progression-free survival (PFS) in ccRCC patients.
Main Results:
- A CXCL7 plasma level cut-off of 250 ng/mL was identified for predicting PFS.
- Patients with baseline CXCL7 >250 ng/mL exhibited significantly longer PFS (HR 0.323, P=0.001), a finding validated retrospectively.
- CXCL7 levels did not impact PFS in bevacizumab-treated patients, suggesting treatment specificity.
Conclusions:
- CXCL7 demonstrates potential as a predictive biomarker for sunitinib efficacy in ccRCC.
- This discovery could facilitate tailored treatment selection for ccRCC patients receiving sunitinib.
More Related Videos
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017